Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | PET/CT in multiple myeloma monitoring

Aurore Perrot • 31 Aug 2020
EBMT 2020
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Thalidomide
CASSIOPEIA

Aurore Perrot, MD, PhD, University Hospital Antwerp, Vandoeuvre-lès-Nancy, France, discusses the prognostic value of positron emission tomography/computer tomography (PET/CT) in transplant-eligible, newly-diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Aurore Perrot

0:48
The role of transplant in myeloma
Aurore Perrot • 9 Sep 2021
2:23
Real-world data: treatment pathways for myeloma patients in France
Aurore Perrot • 9 Sep 2021
0:40
Moving towards a cure for myeloma
Aurore Perrot • 9 Sep 2021
5:24
IFM 209 update: 4-year extended follow-up of transplantation outcomes in myeloma
Aurore Perrot • 7 Dec 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals